Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations-Reference-Cited by-同舟云学术

Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations

Published:2007-01-04 Issue:2 Volume:63 Page:143-149
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Uno Tsukasa,Niioka Takenori,Hayakari Makoto,Yasui-Furukori Norio,Sugawara Kazunobu,Tateishi Tomonori

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-006-0251-7.pdf

Reference28 articles.

1. Wallmark B, Jaresten BM, Larsson H, Ryberg B, Brandstrom A, Fellenius E (1983) Differentiation among inhibitory actions of omeprazole, cimetidine, and SCN- on gastric acid secretion. Am J Physiol 245:G64–G71

2. Howden CW (1991) Clinical pharmacology of omeprazole. Clin Pharmacokinet 20:38–49

3. Maton PN (1991) Omeprazole. N Engl J Med 324:965–975

4. Lind T, Megraud F, Unge P, Bayerdorffer E, O’morain C, Spiller R, Veldhuyzen Van Zanten S, Bardhan KD, Hellblom M, Wrangstadh M, Zeijlon L, Cederberg C (1999) The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116:248–253

5. Tytgat GN (1994) Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 8:359–368

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeled Hepatic/Plasma Exposures of Omeprazole Prescribed Alone in Cytochrome P450 2C19 Poor Metabolizers Are Likely Associated with Hepatic Toxicity Reported in a Japanese Adverse Event Database;Biological and Pharmaceutical Bulletin;2024-05-24

2. Prediction of Omeprazole Pharmacokinetics and its Inhibition on Gastric Acid Secretion in Humans Using Physiologically Based Pharmacokinetic-Pharmacodynamic Model Characterizing CYP2C19 Polymorphisms;Pharmaceutical Research;2023-05-24

3. Performance Verification of CYP2C19 Enzyme Abundance Polymorphism Settings within the Simcyp Simulator v21;Metabolites;2022-10-20

4. Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug–Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole;European Journal of Drug Metabolism and Pharmacokinetics;2020-10-16

5. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors;Pharmacological Research;2020-02